Skip to main content

FDA approves Celgene's bone marrow cancer treatment

The U.S. Food and Drug Administration said on Friday it had approved Celgene Corp's treatment, Inrebic, for certain forms of bone marrow cancer.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.